Atossa Therapeutics announced that the Patent Trial and Appeal Board found all claims under U.S. Patent No. 11,572,334 unpatentable, but the company will not appeal this decision and will instead pursue a new Continuation Patent Application for (Z)-endoxifen, while also announcing a new patent issuance with 31 claims.